SEARCH

SEARCH BY CITATION

References

  • 1
    Bradshaw C, Pierce L, Tabrizi S. Screening injecting drug users for sexually transmitted infections and blood borne viruses using street outreach and self collected sampling. Sex Transm Infect. 2005;81:538.
  • 2
    Health Outcomes International, National Centre in HIV Epidemiology and Clinical Research, Drummond M. Return on Investment in Needle and Syringe Programs in Australia. Canberra ( AUST ) : Commonwealth Department of Health and Ageing; 2002 [cited 2010 May 9]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/2C9410E4A867F2EBCA257650000077B9/$File/roirep.pdf.
  • 3
    National Centre in HIV Epidemiology and Clinical Research. Return on Investment 2: Evaluating the Cost-effectiveness of Needle and Syringe Programs in Australia 2009. Canberra ( AUST ) : Commonwealth Department of Health and Ageing; 2009 [cited 2010 Apr 8]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/C562D0E860733E9FCA257648000215C5/$File/return2.pdf.
  • 4
    Maher L, Chant K, Jalaludin B, Sargent P. Risk behaviours and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol. 2004;19:111420.
  • 5
    National Centre in HIV Epidemiology and Clinical Research. Bloodborne viral and Sexually Transmitted Infections in Aboriginal and Torres Strait Islander People: Surveillance and Evaluation Report. Sydney ( AUST ) : University of New South Wales; 2009.
  • 6
    National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, Viral Hepatitis and Sexually Transmissible Infections in Australia. Annual Surveillance Report. Sydney ( AUST ) : University of New South Wales; 2009.
  • 7
    Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis-C. Hepatitis C Virus Projections Working Group: Estimates and Projections of the Hepatitis C Virus Epidemic in Australia 2006. Sydney ( AUST ) : National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; 2006.
  • 8
    Department of Health and Ageing. Third National Hepatitis C Strategy 2010–2013. Canberra ( AUST ) : Commonwealth of Australia; 2010 [cited 2010 May 8]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-natioal-strategies-2010-hcv/$File/hcv.pdf.
  • 9
    MacDonald M, Wodak A, Ali R, et al. HIV prevalence and risk behaviour in needle exchange attenders: a national study. Med J Aust. 1997;166:23740.
  • 10
    MacDonald M, Wodak A, Dolan K, et al. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997. Med J Aust. 2000;172:5761.
  • 11
    Maher L, Joing Li, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006;101:1499508.
  • 12
    Bourgois P, Prince B, Moss A. The everyday violence of hepatitis C among young women who inject drugs in San Francisco. Human Organization. 2004;63(3):25364.
  • 13
    Strathdee SA, Lozada R, Pollini RA, Brouwer KC, Mantsios A, Abramovitz DA, et al. Individual, social, and environmental influences associated with HIV infection among injection drug users in Tijuana, Mexico. Journal of Acquired Immune Deficiency Syndrome. 2008;47(3):36976.
  • 14
    Aboriginal Health & Medical Research Council and Mandala Consulting. Increasing Access to Services in NSW for Aboriginal People at Risk of Contracting or Who have Blood Borne Infections. Sydney ( AUST ) : AH&MRC Consultancy Service; 2004.
  • 15
    Butler T, Papanastasiou C. National Prison Entrants’ Bloodborne Virus and Risk Behaviour Survey Report 2004 & 2007. Canberra ( AUST ) : Curtin University, National Drug Research Institute; 2008.
  • 16
    Steering Committee for the Review of Government Service Provision. Report on Government Services 2011. Canberra ( AUST ) : Commonwealth Productivity Commission; 2011.
  • 17
    Black E, Dolan K, Wodak A. Supply, Demand and Harm Reduction Strategies in Australian Prisons: Implementation, Cost and Evaluation. Canberra ( AUST ) : Australian National Council on Drugs; 2004. ANCD Research Paper No.: 9.
  • 18
    Miller E, Hellard M, Bowden S, Bharadwaj M, Aitken C. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J Infect. 2009;58:37582.
  • 19
    Falster K, Kaldor K, Maher L, on behalf of collaboration of Australian Needle and Syringe Programs. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995–2004. J Urban Health. 2009;86:10618.
  • 20
    Macalino G, Hou J, Kumar M, Taylor L, Sumantera I, Rich J. Hepatitis C and incarcerated populations. Int J Drug Policy. 2004;15:10314.
  • 21
    Boulos D, Yan P, Schanzer D, Remis RS, Archibald CP. Estimates of HIV prevalence and Incidence in Canada, 2005. Can Commun Dis Rep. 2006;32:16574.
  • 22
    Topp L, Iversen J, Wand H, Day C, Kaldor J, Maher L. Representativeness of injecting drug users who participate in HIV surveillance results from Australia's Needle and Syringe Program Survey. Journal of Acquired Immune Deficiency Syndrome. 2008, 47:6328.
  • 23
    Johnson T, Fendrich M. Modelling sources of self-report bias in a survey of drug use epidemiology. Ann Epidemiol. 2005;15:3819.
  • 24
    Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviours among intravenous drug users. Addiction. 1993;88:51725.
  • 25
    Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:71019.
  • 26
    White B, Day C, Maher L. Self reported drug use and risk behaviour among injecting drug users: self versus assisted questionnaire completion. AIDS Care. 2007;19:4417.